Prevalence of hyperhomocysteinaemia in chronic kidney disease and effect of supplementation of folic acid and vitamin B12 on cardiovascular mortality

Journal, Indian Academy of Clinical Medicine

Volumn 14, Issue 1, 2013, Pages 33-36

  Nand, N ^a   Sharma, M ^a   Mittal, N ^a  

^a POST GRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Glomerular filtration rate; Unstable angina; Venous thrombotic events

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 84877848475     PISSN: 09723560     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients. Left ventricular hypertrophy, ischemic heart diseaseand cardiac failure. Semin Dial 2003; 16: 111-7.
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-22.
3. Wollesen F, Brattstrom B, Refsum H et al. Plasma total homocysteine and cysteine in relation to glomerular filtration rate.Kidney Int. 1999; 55: 1028-35.
4. Mallamaci F. Homocysteine and risk in end-stage renal disease: a matter of context. Kidney Int 2006; 69: 204-7.
5. Finkelstein J. Regulation of homocysteine metabolism. Carmel R, Jacobsen DW, eds. In: Homocysteine in Health and Disease. Cambridge, UK: Cambridge University Press; 2001: 92-9.
6. Bønaa KH, Njolstad I, Ueland PM. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
7. Lonn E, Yusuf S, Arnold MJ. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
8. Johannes F, Mann E, Sheridan P, Matthew J et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease-results of the renal HOPE-2 study. Nephrol Dial Tranplant 2008; 23: 643-5.
9. thedn. Elsevier, New Delhi, 2006, p84-5.
10. Muntner P, He J, Astor BC et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities study. J Am Soc Nephrol 2005; 16: 529-38.
11. Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in endstage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-48.
12. Jungers P, Joly D, Massy Z et al. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant 1999; 14: 2903-06.
13. Bostom AG, Shemin D, Lapane KL. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147-52.
14. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-70.
15. Zoungas S, McGrath BP, Branley P. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomised, controlled trial. J Am Coll Cardiol 2006; 47: 1108-16.
16. Massy ZA. Potential strategies to normalize the levels of homocysteine in chronic renal failure patients. Kidney Int 2003; 63: 134-6.